Should I buy or sell Vaxxinity stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VAXX shares. View VAXX analyst ratings or view top-rated stocks .

What is Vaxxinity's stock price target for 2024?

1 brokers have issued twelve-month price targets for Vaxxinity's stock. Their VAXX share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 1,418.4% from the stock's current price. View analysts price targets for VAXX or view top-rated stocks among Wall Street analysts .

How have VAXX shares performed in 2024?

Vaxxinity's stock was trading at $0.85 at the start of the year. Since then, VAXX shares have decreased by 45.8% and is now trading at $0.4610. View the best growth stocks for 2024 here .

When is Vaxxinity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VAXX earnings forecast .

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04.

What ETF holds Vaxxinity's stock?

Amplify Treatments, Testing and Advancements ETF holds 35,725 shares of VAXX stock, representing 0.58% of its portfolio.

When did Vaxxinity IPO?

Vaxxinity (VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VAXX

Vaxxinity (VAXX) Stock Price, News & Analysis

→ 2024's Must-Have Guide: Master Crypto Investment Today (From Darwin) (Ad)

Free VAXX Stock Alerts

$0.43

-0.03 (-6.84%)

(As of 12:27 PM ET)

Compare

Today's Range: $0.43
▼
$0.48
50-Day Range: $0.42
▼
$0.86
52-Week Range: $0.39
▼
$3.10

Volume: 80,336 shs
Average Volume: 396,085 shs
Market Capitalization: $54.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Vaxxinity alerts:

Vaxxinity MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,418.4% Upside
$7.00 Price Target
Short Interest: Bearish
9.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.42) to ($0.40) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.18 out of 5 stars

Medical Sector

728th out of 918 stocks

Pharmaceutical Preparations Industry

333rd out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Vaxxinity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Vaxxinity has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.00% of the float of Vaxxinity has been sold short.
Short Interest Ratio / Days to Cover
Vaxxinity has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Vaxxinity has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vaxxinity does not currently pay a dividend.
Dividend Growth
Vaxxinity does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VAXX.

0.6

News and Social Media Coverage

Search Interest
Only 16 people have searched for VAXX on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
MarketBeat Follows
4 people have added Vaxxinity to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaxxinity insiders have not sold or bought any company stock.
Percentage Held by Insiders
59.07% of the stock of Vaxxinity is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.95% of the stock of Vaxxinity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Vaxxinity are expected to grow in the coming year, from ($0.42) to ($0.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaxxinity is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaxxinity is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaxxinity has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About Vaxxinity Stock (NASDAQ:VAXX)

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

VAXX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VAXX Stock News Headlines

April 10, 2024 | americanbankingnews.com

Vaxxinity (NASDAQ:VAXX) Trading 2.1% Higher

March 28, 2024 | globenewswire.com

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

April 19, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

March 27, 2024 | investorplace.com

VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023

March 27, 2024 | globenewswire.com

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

March 7, 2024 | globenewswire.com

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

February 15, 2024 | finance.yahoo.com

Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels

February 15, 2024 | finance.yahoo.com

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

April 19, 2024 | Insiders Exposed (Ad)

The Hard Truth About Investing For Retirement

February 15, 2024 | globenewswire.com

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

February 13, 2024 | finance.yahoo.com

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

January 30, 2024 | finance.yahoo.com

Vaxxinity, UF Join Forces Against Neurodegenerative Diseases

January 30, 2024 | finance.yahoo.com

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

January 19, 2024 | finance.yahoo.com

Vaxxinity & UCF to Collaborate on Space Medicine Research

January 18, 2024 | finance.yahoo.com

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

January 3, 2024 | finance.yahoo.com

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

December 12, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

November 21, 2023 | markets.businessinsider.com

Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others

November 20, 2023 | foxnews.com

Several Alzheimer's vaccines enter clinical trials amid breakthrough treatments' success

November 20, 2023 | msn.com

Researchers return to Alzheimer's vaccines, buoyed by recent drug success

November 13, 2023 | finance.yahoo.com

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

November 8, 2023 | finance.yahoo.com

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 10, 2023 | finance.yahoo.com

Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline

September 7, 2023 | finance.yahoo.com

Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)

August 11, 2023 | finance.yahoo.com

Vaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s Treatment

August 10, 2023 | finance.yahoo.com

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

August 9, 2023 | finance.yahoo.com

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

See More Headlines

Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VAXX
CUSIP: N/A
CIK: 1851657
Web: www.vaxxinity.com
Phone: 254-244-5739
Fax: N/A
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +1,490.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-56,930,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -192.58%
Return on Assets: -88.04%

Debt

Debt-to-Equity Ratio: 0.99
Current Ratio: 1.89
Quick Ratio: 1.89

Sales & Book Value

Annual Sales: $70,000.00
Price / Sales: 796.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.11 per share
Price / Book: 4.00

Miscellaneous

Outstanding Shares: 126,750,000
Free Float: 51,878,000
Market Cap: $55.77 million
Optionable: Not Optionable
Beta: 2.39

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Louis Garfield Reese IV (Age 42)
Co-Founder & Executive Chairman of the Board
Comp: $83.28k
Ms. Mei Mei Hu J.D. (Age 41)
CEO & Director
Comp: $551.73k
Mr. Jason Pesile CPA (Age 51)
M.B.A., Chief Accounting Officer
Dr. Jean-Cosme Dodart Ph.D.
Chief Scientific Officer
Ms. Sumita Ray J.D. (Age 50)
Chief Legal & Administrative Officer
Mr. Jon Harrison
Chief Government Officer
Mr. Mark Joinnides MSE
Chief of Staff
Ms. Amy B. Fix M.B.A.
M.S., R.A.C., Head of Regulatory

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VAXX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxxinity stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VAXX shares.
View VAXX analyst ratings or view top-rated stocks.
What is Vaxxinity's stock price target for 2024?: 1 brokers have issued twelve-month price targets for Vaxxinity's stock. Their VAXX share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 1,418.4% from the stock's current price.
View analysts price targets for VAXX or view top-rated stocks among Wall Street analysts.
How have VAXX shares performed in 2024?: Vaxxinity's stock was trading at $0.85 at the start of the year. Since then, VAXX shares have decreased by 45.8% and is now trading at $0.4610.
View the best growth stocks for 2024 here.
When is Vaxxinity's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VAXX earnings forecast.

How were Vaxxinity's earnings last quarter?: Vaxxinity, Inc. (NASDAQ:VAXX) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04.
What ETF holds Vaxxinity's stock?: Amplify Treatments, Testing and Advancements ETF holds 35,725 shares of VAXX stock, representing 0.58% of its portfolio.
When did Vaxxinity IPO?: Vaxxinity (VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.
How do I buy shares of Vaxxinity?: Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VAXX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial